Ilia I. Ouspenski

Array ( [id] => 8239866 [patent_doc_number] => 20120148597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-14 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO CTLA-4' [patent_app_type] => utility [patent_app_number] => 13/399448 [patent_app_country] => US [patent_app_date] => 2012-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 32341 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13399448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8220794 [patent_doc_number] => 20120135001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-31 [patent_title] => 'COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DASATINIB FOR THE TREATMENT OF PROLIFERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 13/371514 [patent_app_country] => US [patent_app_date] => 2012-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 20136 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13371514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8227283 [patent_doc_number] => 20120141494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-07 [patent_title] => 'FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB' [patent_app_type] => utility [patent_app_number] => 13/368710 [patent_app_country] => US [patent_app_date] => 2012-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 11926 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13368710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9545497 [patent_doc_number] => 20140170143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'USE OF AN ANTI-CD200 ANTIBODY FOR PROLONGING THE SURVIVAL OF ALLOGRAFTS' [patent_app_type] => utility [patent_app_number] => 13/983415 [patent_app_country] => US [patent_app_date] => 2012-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 45681 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13983415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8289281 [patent_doc_number] => 20120177581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-12 [patent_title] => 'BYSTANDER IMMUNE SUPPRESSION AS A PREDICTOR FOR RESPONSE TO A VACCINE' [patent_app_type] => utility [patent_app_number] => 13/343975 [patent_app_country] => US [patent_app_date] => 2012-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 7796 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13343975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001484 [patent_doc_number] => 09045562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Compositions and methods for modulating lymphocyte activity' [patent_app_type] => utility [patent_app_number] => 13/341611 [patent_app_country] => US [patent_app_date] => 2011-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 99 [patent_figures_cnt] => 93 [patent_no_of_words] => 66448 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13341611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9323582 [patent_doc_number] => 08658603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-02-25 [patent_title] => 'Compositions and methods for inducing an immune response' [patent_app_type] => utility [patent_app_number] => 13/331354 [patent_app_country] => US [patent_app_date] => 2011-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 19 [patent_no_of_words] => 25097 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13331354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9345213 [patent_doc_number] => 08664360 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-04 [patent_title] => 'BSL3 polypeptides' [patent_app_type] => utility [patent_app_number] => 13/331540 [patent_app_country] => US [patent_app_date] => 2011-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 46 [patent_no_of_words] => 43658 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13331540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8184125 [patent_doc_number] => 20120114649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-10 [patent_title] => 'COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/332164 [patent_app_country] => US [patent_app_date] => 2011-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 25652 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0114/20120114649.pdf [firstpage_image] =>[orig_patent_app_number] => 13332164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9244810 [patent_doc_number] => 08609089 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-17 [patent_title] => 'Compositions of PD-1 antagonists and methods of use' [patent_app_type] => utility [patent_app_number] => 13/332154 [patent_app_country] => US [patent_app_date] => 2011-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 25694 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13332154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9073900 [patent_doc_number] => 08551477 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2013-10-08 [patent_title] => 'Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same' [patent_app_type] => utility [patent_app_number] => 13/329811 [patent_app_country] => US [patent_app_date] => 2011-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16658 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13329811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8870364 [patent_doc_number] => 08465740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-18 [patent_title] => 'Regulatory T cell mediator proteins and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/326792 [patent_app_country] => US [patent_app_date] => 2011-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10374 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13326792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10505266 [patent_doc_number] => 09233125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-12 [patent_title] => 'Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer' [patent_app_type] => utility [patent_app_number] => 13/993396 [patent_app_country] => US [patent_app_date] => 2011-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10494 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13993396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10919216 [patent_doc_number] => 20140322235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'ANTI-CD277 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/994277 [patent_app_country] => US [patent_app_date] => 2011-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 21841 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13994277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10050841 [patent_doc_number] => 09090708 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-28 [patent_title] => 'Porcine CTLA-4 for xenograft-specific immunosuppression' [patent_app_type] => utility [patent_app_number] => 13/316791 [patent_app_country] => US [patent_app_date] => 2011-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 23 [patent_no_of_words] => 7692 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13316791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8328672 [patent_doc_number] => 08236767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-08-07 [patent_title] => 'Methods for treating inflammation using B7-H4 polypeptides and fragments thereof' [patent_app_type] => utility [patent_app_number] => 13/323360 [patent_app_country] => US [patent_app_date] => 2011-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 19 [patent_no_of_words] => 15030 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13323360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9015550 [patent_doc_number] => 20130230514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/312201 [patent_app_country] => US [patent_app_date] => 2011-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 25670 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13312201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8239843 [patent_doc_number] => 20120148579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-14 [patent_title] => 'ANTIBODIES TO OX-2/CD200 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/311910 [patent_app_country] => US [patent_app_date] => 2011-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 73 [patent_figures_cnt] => 73 [patent_no_of_words] => 31843 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13311910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8802523 [patent_doc_number] => 08440797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-05-14 [patent_title] => 'Human monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 13/311124 [patent_app_country] => US [patent_app_date] => 2011-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33192 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13311124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8523263 [patent_doc_number] => 20120322672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-20 [patent_title] => 'METHOD FOR GENERATING AND SELECTING ANTIBODIES AGAINST TARGET PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/300534 [patent_app_country] => US [patent_app_date] => 2011-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 30391 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13300534 [rel_patent_id] =>[rel_patent_doc_number] =>)